- Home
- NNY vs ACRS Comparison
NNY vs ACRS Comparison
Compare NNY & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- ACRS
- Stock Information
- Founded
- NNY 1987
- ACRS 2012
- Country
- NNY United States
- ACRS United States
- Employees
- NNY N/A
- ACRS N/A
- Industry
- NNY Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- NNY Finance
- ACRS Health Care
- Exchange
- NNY Nasdaq
- ACRS Nasdaq
- Market Cap
- NNY 155.8M
- ACRS 170.9M
- IPO Year
- NNY N/A
- ACRS 2015
- Fundamental
- Price
- NNY $8.28
- ACRS $1.53
- Analyst Decision
- NNY
- ACRS Strong Buy
- Analyst Count
- NNY 0
- ACRS 7
- Target Price
- NNY N/A
- ACRS $11.67
- AVG Volume (30 Days)
- NNY 50.9K
- ACRS 1.2M
- Earning Date
- NNY 01-01-0001
- ACRS 05-06-2025
- Dividend Yield
- NNY 4.04%
- ACRS N/A
- EPS Growth
- NNY N/A
- ACRS N/A
- EPS
- NNY N/A
- ACRS N/A
- Revenue
- NNY N/A
- ACRS $18,720,000.00
- Revenue This Year
- NNY N/A
- ACRS N/A
- Revenue Next Year
- NNY N/A
- ACRS N/A
- P/E Ratio
- NNY N/A
- ACRS N/A
- Revenue Growth
- NNY N/A
- ACRS N/A
- 52 Week Low
- NNY $7.58
- ACRS $0.95
- 52 Week High
- NNY $8.87
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- NNY 53.55
- ACRS 28.64
- Support Level
- NNY $8.11
- ACRS $1.57
- Resistance Level
- NNY $8.33
- ACRS $1.78
- Average True Range (ATR)
- NNY 0.09
- ACRS 0.10
- MACD
- NNY 0.00
- ACRS 0.02
- Stochastic Oscillator
- NNY 77.27
- ACRS 17.74
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.